TYSABRI Global Observational Program in Safety
NCT00477113 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2207
Last updated 2015-06-22
Summary
The Primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAE) in participants with multiple sclerosis (MS) treated with Tysabri (natalizumab).
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Director · Biogen
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-01-31
- Primary Completion
- 2015-05-31
- Completion
- 2015-05-31
Countries
- United States
Study Locations
More Related Trials
-
Ireland Natalizumab (TYSABRI) Observational Program
NCT01943526 ·Status: COMPLETED
-
Natalizumab (Tysabri) Re-Initiation of Dosing
NCT00297232 ·Status: TERMINATED ·Phase: PHASE3
-
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants
NCT01485003 ·Status: COMPLETED
-
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
NCT03399981 ·Status: COMPLETED
-
Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS
NCT02965170 ·Status: COMPLETED
-
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
NCT00536120 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
NCT01455220 ·Status: COMPLETED ·Phase: NA
-
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
NCT04832399 ·Status: COMPLETED
-
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
NCT04580381 ·Status: COMPLETED
-
Natalizumab Re-Initiation of Dosing
NCT00306592 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
NCT00424788 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri
NCT02137109 ·Status: COMPLETED
-
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
NCT06127095 ·Status: COMPLETED
-
Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study
NCT00937677 ·Status: COMPLETED
-
Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients
NCT01658384 ·Status: COMPLETED
-
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
NCT01071512 ·Status: COMPLETED ·Phase: NA
-
Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS
NCT00884481 ·Status: COMPLETED
-
JC-Virus (JCV) Antibody Program
NCT01070823 ·Status: COMPLETED
-
A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients
NCT00871780 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®
NCT04115488 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
NCT02159573 ·Status: COMPLETED
-
Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
NCT01706107 ·Status: TERMINATED
-
A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
NCT05925049 ·Status: ACTIVE_NOT_RECRUITING
-
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical
NCT01330498 ·Status: COMPLETED
-
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
NCT00464074 ·Status: COMPLETED